Tower Research Capital LLC (Trc) Fate Therapeutics Inc Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 14,728 shares of FATE stock, worth $13,402. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,728
Previous 6,885
113.91%
Holding current value
$13,402
Previous $24,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding FATE
# of Institutions
167Shares Held
101MCall Options Held
41.3KPut Options Held
15.9K-
Redmile Group, LLC San Francisco, CA12.9MShares$11.7 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$9.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.21 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$4.4 Million0.16% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.38MShares$3.99 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $88.3M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...